Profile data is unavailable for this security.
About the company
Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.
- Revenue in HKD (TTM)0.00
- Net income in HKD-425.03m
- Incorporated2017
- Employees96.00
- LocationBrii Biosciences Ltd3rd Floor, Building 7Zhongguancun Dongsheng, InternationalNo. 1 North Yongtaizhuang Road, HaidianBEIJING 100192ChinaCHN
- Websitehttps://www.briibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirnaomics Ltd | 13.90m | -109.54m | 782.72m | 52.00 | -- | -- | -- | 56.33 | -1.33 | -1.33 | 0.161 | -0.3803 | 0.0637 | -- | -- | 201,380.40 | -36.30 | -80.21 | -216.85 | -100.49 | 67.44 | -- | -570.30 | -27,838.86 | -- | -8.20 | -- | -- | -- | -- | 34.70 | -- | -38.10 | -- |
| JW (Cayman) Therapeutics Co Ltd | 201.09m | -698.72m | 907.91m | 292.00 | -- | 0.8827 | -- | 4.51 | -1.68 | -1.68 | 0.4847 | 2.47 | 0.1046 | 1.34 | 9.59 | 715,620.90 | -36.34 | -35.14 | -47.41 | -39.06 | 55.52 | -- | -347.47 | -898.77 | 1.45 | -1,808.42 | 0.2907 | -- | -8.99 | -- | 23.10 | -- | -32.98 | -- |
| Sunho Biologics Inc | 0.00 | -92.87m | 1.00bn | 128.00 | -- | 1.84 | -- | -- | -0.6153 | -0.6153 | 0.00 | 3.48 | 0.00 | -- | -- | 0.00 | -14.33 | -- | -15.84 | -- | -- | -- | -- | -- | 6.57 | -- | 0.1242 | -- | -- | -- | 39.74 | -- | -- | -- |
| B&K Corp Ltd | 295.27k | -206.60m | 1.10bn | 100.00 | -- | 11.54 | -- | 3,737.66 | -1.76 | -1.76 | 0.0025 | 0.8128 | -- | -- | -- | -- | -- | -- | -- | -- | 92.34 | -- | -69,968.59 | -- | -- | -- | 0.0371 | -- | -44.70 | -- | -101.78 | -- | -- | -- |
| Brii Biosciences Ltd | 0.00 | -425.03m | 1.12bn | 96.00 | -- | 0.3965 | -- | -- | -0.5839 | -0.5839 | 0.00 | 3.91 | 0.00 | -- | -- | 0.00 | -14.05 | -49.92 | -14.09 | -54.57 | -- | -- | -- | -12,750.27 | -- | -- | 0.003 | -- | -100.00 | -- | -190.66 | -- | -33.13 | -- |
| Kintor Pharmaceutical Ltd | 12.43m | -189.00m | 1.37bn | 136.00 | -- | 5.04 | -- | 110.36 | -0.437 | -0.437 | 0.0287 | 0.5461 | 0.0194 | 10.66 | 1.06 | 73,966.23 | -29.53 | -47.72 | -44.54 | -55.96 | -55.12 | -36.16 | -1,521.00 | -8,974.73 | 0.4222 | -33.76 | 0.2881 | -- | -- | -- | 85.36 | -- | -53.11 | -- |
| Wuhan YZY Biopharma Co Ltd | 164.04m | -88.28m | 1.40bn | 106.00 | -- | -- | -- | 8.56 | -0.4554 | -0.4554 | 0.8462 | -0.1602 | 0.5805 | 11.54 | 13.96 | 1,451,683.00 | -31.24 | -- | -133.35 | -- | 63.96 | -- | -53.82 | -- | 0.9019 | -24.38 | 1.21 | -- | -- | -- | 49.09 | -- | -- | -- |
| HighTide Therapeutics Inc | 0.00 | -329.39m | 1.45bn | 57.00 | -- | 3.65 | -- | -- | -0.7286 | -0.7286 | 0.00 | 0.6934 | 0.00 | -- | -- | 0.00 | -49.50 | -- | -63.55 | -- | -- | -- | -- | -- | -- | -- | 0.2129 | -- | -- | -- | 59.35 | -- | -- | -- |
| Immunotech Biopharm Ltd | 0.00 | -252.85m | 1.57bn | 173.00 | -- | -- | -- | -- | -0.4518 | -0.4518 | 0.00 | -0.2878 | 0.00 | -- | -- | 0.00 | -37.04 | -36.20 | -186.73 | -45.67 | -- | -- | -- | -- | 0.0712 | -6.63 | 1.48 | -- | -- | -- | 44.18 | -- | 5.95 | -- |
Data as of Feb 16 2026. Currency figures normalised to Brii Biosciences Ltd's reporting currency: Hong Kong Dollar HKD
0.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| American Century Investment Management, Inc.as of 05 Feb 2026 | 750.50k | 0.10% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 581.50k | 0.08% |
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 364.00k | 0.05% |
| Allianz Global Investors Asia Pacific Ltd.as of 30 Jun 2025 | 322.50k | 0.04% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 128.37k | 0.02% |
| UBS Asset Management (Hong Kong) Ltd.as of 30 Jun 2022 | 26.50k | 0.00% |
| DFA Australia Ltd.as of 30 Nov 2025 | 1.29k | 0.00% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 88.00 | 0.00% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 31 Oct 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
